Raising the gold standard for therapeutic protein expression

As market demand continues to rise for more potent and effective therapeutics, drug developers are identifying novel disease targets and biological mechanisms for which medicines can be developed. As a consequence biologic pipelines are evolving from standard antibody formats to next-generation biologics. Now more than ever before, there is a real need for robust and scalable expression platforms that can keep pace with these requirements.

We strive to help you develop next generation biotherapeutics as quickly and reliably as possible. With more than 35 years of experience providing mammalian expression, process development and manufacturing services, we are ideally placed to supply you with a robust and versatile expression platform to optimize your production.

The GS Xceed® Expression System is a market-leading expression technology platform. This robust, fully integrated, scalable system includes host cell lines, vectors, and access to optimized media and feeds, as well as comprehensive methods and processes.

As biopharmaceutical development continues to evolve, we are committed to ongoing technology advancements to our GS Xceed® Toolbox to continue to meet your needs. The combination of this ongoing innovation, advanced, proprietary technology and our exceptional expertise will help improve your efficiency and help reduce time to market.

Learn more

Leveraging Platforms to Create Vaccines at Pandemic Speed

View GEN On-Demand Webinar

Meet the challenge of complex protein expression with GS piggyBac™ 

Introducing the next stage in the evolution of our GS Xceed® Toolbox, GS piggyBac™- a unique and versatile cell line engineering technology.  A proven transposon-based technology that preferentially targets stable regions of the genome associated with highly expressed genes.

The GS piggyBac™ system uses an engineered hyperactive piggyBac™ transposase enzyme to insert GS Xceed® expression vector cargos into the host cell genome with high efficiency with the following benefits:

  • Combining our GS System® with piggyBac™ transposon technology results in increased yields versus GS System® alone with both pools and clones1,2
  • Enhanced performance of GS piggyBac™ is observed with low versus high expressing monoclonal antibodies1,2
  • Accommodating a large DNA cargo (> 200kb) makes GS piggyBac™ highly suited to support cell line engineering needed to enhance complex protein expression3
  • Preferentially targeting genetically stable parts of the genome at high efficiency has the potential to improve cell line stability.4, 5, 6

Available to new and existing GS Expression System® license holders. Contact us to learn more

Recent Publications

View articles

Utilising GS piggyBac™ transposon technology to enhance the performance of the Lonza GS Gene Expression System in stable CHO pool construction

Request poster


Tools to meet the challenge of complex protein expression

View Webinar

Right first time: Successfully progressing biotherapeutics from discovery to the clinic

View Webinar

Accelerating translation of protein biologics into clinical development: current trends

View Webinar  


Related content

Technical Support
At Lonza, we strive to deliver sustainable value to you through continuous technology development and knowledge sharing. We are committed to providing the support and expertise that you need on the journey from gene to commercial product.
Through our partnership with BioWa, Inc. on the POTELLIGENT® CHOK1SV® cell line technology, we can help you produce antibodies with enhanced ADCC resulting in improved efficacy. Antibodies produced by this cell line can exert potent cytotoxic effects ...
XS Technologies®
With over 30 years of experience in microbial expression, we can help you optimize the production of biotherapeutics. Our versatile XS Technologies® offer an extensive microbial expression toolbox, providing highly productive and scalable platforms to inc...
Cell Line Development
A critical factor in reducing the production costs of biopharmaceuticals is the development of cell lines that produce a high yield of product with the desired critical quality attributes. Lonza cell culture teams create cell lines for a wide variety of p...
Light Path™ Protein Production
Light Path™ Protein Production – gene to product offerings supporting preclinical and phase I studies for microbial or mammalian proteins.
Developability Assessment
The path from discovery to commercialization is often long and expensive. Driving down costs and timelines can help improve patient access and provide development efficiencies. Lonza’s Developability Assessment reduces development cost and time and can en...
Immunogenicity Assessment
All biotherapeutic proteins have the potential to elicit an immune response when administered to humans. Lonza's Epibase® in silico and in vitro immunogenicity screening services address the challenge of unwanted immune responses throughout the drug devel...